Glucagon-like peptide (GLP)-1 is an incretin hormone with several antidiabetic functions including stimulation of glucose-dependent insulin secretion, increase in insulin gene expression and beta-cell survival. Despite the initial technical difficulties and profound inefficiency of direct gene transfer into the pancreas that seriously restricted in vivo gene transfer experiments with GLP-1, recent exploitation of various routes of gene delivery and alternative means of gene transfer has permitted the detailed assessment of the therapeutic efficacy of GLP-1 in animal models of type 2 diabetes (T2DM). As a result, many clinical benefits of GLP-1 peptide/analogues observed in clinical trials involving induction of glucose tolerance, reduction of hyperglycaemia, suppression of appetite and food intake linked to weight loss have been replicated in animal models using gene therapy. Furthermore, GLP-1-centered gene therapy not only improved insulin sensitivity, but also reduced abdominal and/or hepatic fat associated with obesity-induced T2DM with drastic alterations in adipokine profiles in treated subjects. Thus, a comprehensive assessment of recent GLP-1-mediated gene therapy approaches with detailed analysis of current hurdles and resolutions, is discussed.
Introduction
An incretin effect is defined as a biologic process where orally taken carbohydrates induce the release of intestinal hormones augmenting insulin secretion more than what could be achieved with intravenous glucose delivery (Ref. 1) . These hormones are released from the intestinal mucosa to orchestrate glucose-induced insulin secretion (insulinotropic effect) from pancreatic beta cells. Therefore, incretin hormones are crucial in the maintenance of postprandial glucose levels by facilitating glucose transport into peripheral tissues (Ref. 2) . Gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two incretin hormones with insulinotropic effect in humans, which is responsible for 70% of postprandial glucosedependent insulin secretion (Ref. 3) . Some of the remaining insulinotropic activity can be attributed in part to neurotransmitters, such as vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) (Refs 4, 5) .
GLP-1 is one of the two essential gut-derived incretin hormones involved in the modulation of glucose homoeostasis (Fig. 1) . Its insulinotropic activity has been demonstrated both in preclinical and clinical studies (Refs 6, 7). After ingestion of a meal, GLP-1 is released into the bloodstream where it stimulates glucosedependent insulin release and insulin biosynthesis in pancreatic beta cells (Ref. 8 ) through a G-protein-coupled receptor (GLP-1R) (Ref. 9) . While carbohydrates are the most effective agent causing GLP-1 secretion, proteins and fat also contribute to the secretion of GLP-1 (Refs 10, 11). Apart from its insulinotropic action, GLP-1 interferes with glucagon release (Ref. 12 ) and improves age-related glucose intolerance (Ref. 13 ). In addition, GLP-1 possesses mitogenic effects resulting in cellular differentiation (Ref. 14) and increased beta-cell mass (Ref. 15 ). Weight loss due to reduced appetite and food intake (Ref. 16 ) is also observed as a result of suppression of gastrointestinal motility and secretion (Ref. 17) . Lastly, GLP-1 displayed beneficial effects in patients with myocardial ischaemia and heart failure (Ref. 18) .
Isoglycaemic glucose tolerance tests demonstrated that type 2 diabetes (T2DM) patients manifested a 50% reduction in the incretin effect, despite a 300% increase in glucose-induced insulin secretion of healthy controls (Ref. 19) . Thus, the loss of incretin response certainly results in glucose intolerance in patients with T2DM, since incretins are the main modulators of postprandial glucose excursions. Interestingly, meal-stimulated GLP-1 response, but not postprandial GIP secretion, was severely reduced in patients with T2DM (Ref. 20) . Moreover, GLP-1 retained its insulinotropic effect in T2DM patients, while no incretin response was obtained with GIP administration (Ref. 21 ). Because GLP-1 infusions restored down-regulated beta-cell response to glucose in T2DM patients (Ref. 22) , GLP-1 has been considered a therapeutic agent for the treatment of T2DM.
GLP-1 is initially synthesised as part of proglucagon, a prohormone consisting of 180 amino acids (Ref. 23 ). Besides GLP-1, several other small peptides glucagon, GLP-2, glicentin and oxyntomodulin are also encoded within proglucagon fragment (Fig. 2) . GLP-1 and glucagon are generated as a result of the differential post-translational processing of preproglucagon in the intestine and pancreas, respectively (Ref. 24) . Therefore, the posttranslational process is carried out by two distinct prohormone convertases specifically expressed in two different tissues, PC2 in pancreas (Ref. 25 ) and PC3 in intestinal L cells (Ref. 26) . In addition, GLP-1 is produced in the hindbrain, primarily in the nucleus of the solitary tract (NTS) to regulate food motivation/ reward (Refs 27, 28) . It is the central GLP-1 production from brainstem neurons, which is responsible for the appearance of meal-related benefits of GLP-1 involving reduction in meal size, meal frequency, food motivation and reward (Refs 28, 29, 30, 31) . GLP-1 production from preproglucagon in non-endocrine tissues is impractical, although, without the expression of the specific prohormone convertase (Ref. 32) . Nonetheless, proglucagon is intracellularly transported to the regulated secretory pathway where it is processed into the smaller peptides.
GLP-1 is a potent stimulator of glucoseinduced insulin release without causing reactive hypoglycaemia (Ref. 33 ). However, GLP-1 has a short biological half-life (2-3 min) due to rapid truncation by the ubiquitous serine protease dipeptidyl peptidase-4 (DPP-4), which limits its therapeutic use (Ref. 3). While frequent injections or larger quantities are needed to compensate for the short biological half-life of GLP-1, viral or nonviral vector gene delivery technologies were developed to provide a constant bioactive GLP-1 production and secretion (Ref. 34) . Because utilisation of the preproglucagon transgene might lead to unpredictable production of glucagon, or other processed peptides with unknown function, gene transfer experiments involving GLP-1 encoding sequence normally is restricted to GLP-1 7-37 transfer rather than the entire preproglucagon cDNA (Fig. 3) . In addition, since the first two amino acids of GLP-1 are essential for its receptor binding, constructs encoding GLP-1 7-37 from a methionine start codon need to be synthesised using a DNA synthesiser. A furin recognition site (RGRR) is introduced into the GLP-1 cDNA following the start codon to facilitate removal of the preceding amino acids by furin endopeptidases to generate the active form of the peptide before secretion. Lastly, a secretory signal peptide is needed to target GLP-1 to the constitutive secretory pathway (CSP) to allow post-translational processing by a signal peptidase facilitating its production and secretion in non-endocrine tissues. Consequently, current progress in gene therapy approaches involving GLP-1 cDNA transfer for diabetes treatment will be highlighted in this manuscript.
Non-viral gene delivery approaches Plasmids
A plasmid-based gene delivery method involving a modified GLP-1 7-37 cDNA with a furin cleavage site between the start codon and GLP-1 coding region was developed to evaluate the consequence of in vivo GLP-1 gene delivery in diabetic animals (Ref. 35) . A single intravenous injection of polyethylenimine (PEI)/pGLP1 complex into Zucker diabetic fatty (ZDF) rats resulted in an increase in glucose-induced insulin secretion with a reduction in blood glucose level for 2 weeks. To increase GLP-1 expression, an SV40 promoter with NF-κB-binding sites was incorporated into the plasmid carrying GLP1 7-37 cDNA with furin cleavage site (Ref. 36) . A single systemic administration of PEI/pGLP1 complex into the diet-induced obese (DIO) mice resulted in increased insulin secretion and decreased blood glucose longer than 2 weeks.
Differential proglucagon processing in the intestine versus pancreas Because GLP-1 must be delivered through a parenteral route and has a short lifespan, a fusion protein consisting of an active human GLP-1 and mouse IgG1 heavy chain constant regions (GLP-1/Fc) was generated to prolong and enhance the therapeutic potency of GLP-1 (Ref. 37) . IgG-Fc homodimerisation would result in the formation of bivalent GLP-1 peptide ligands with longer half-life compared to native GLP-1, since the formation of large molecular weight homodimers slows renal clearance and reduces degradation of the conjugated peptide. The anti-diabetic effects of the GLP-1/Fc plasmid injection took time to develop, as delivery of GLP-1/Fc fusion protein normalised fasting blood glucose levels three months after the first injection in db/db mice resulting in augmented glucose-induced insulin secretion and reduced glucagon release. However, the GLP-1/Fc fusion protein could not penetrate through the blood-brain barrier, so body weight and peripheral insulin sensitivities were not affected by this treatment.
A chitosan-based gene delivery system was constructed by taking advantage of the natural ability of cationic polymers to condense plasmid DNA through electrostatic interaction to protect it from a nuclease attack (Ref. chitosan-based nanocomplexes containing GLP-1-encoding plasmid DNA with a furin recognition site and cytomegalovirus (CMV) promoter was assessed in 12-week-old ZDF rats with overt diabetes mellitus (Ref. 40) . A significant increase in the amount of plasma GLP-1 was detected at day 49 after five injections of chitosan-GLP-1 nanoparticles. In spite of the improvement in glucose tolerance and reduced weight gain in the treated rats, the increase in circulating insulin was transient and only lasted 14 days following the last injection. Intriguingly, subcutaneous (s.c.) injection of the nanocomplexes was more efficient than intramuscular (i.m.) gene delivery presumably due to an inflammatory reaction at the injection site that interfered with vector distribution. The ability of specific chitosan formulations to deliver native GLP-1, DPP-4-resistant GLP-1 analogues and siRNA-targeting DPP-4 mRNA were investigated in a recent in vitro study (Ref. 41) . Chitosan formulations effectively delivered nucleic acid into cell lines resulting in a fivefold increase in DPP-4-resistant GLP-1 analogues compared to native GLP-1. In addition, a DPP-4 gene-silencing approach using chitosan formulation was successful and exhibited reduced toxicity compared to commercially available lipoplex, DharmaFECT.
Because Exendin-4 (Exenatide) is an effective GLP-1R agonist (50% sequence homology) with longer half-life, an Exendin-4 expression system was designed using the two-step transcription amplification method consisting of a dual plasmid, where one plasmid encoded a potent transcription factor and the second plasmid contained a promoter driving the Exendin-4 encoding sequence (Ref. 42 ). An arginine-grafted cyctaminebisacrylamide-diaminohexane polymer (ABP) was chosen as a gene carrier, since it exhibited minimal toxicity and higher transfection efficiency compared to PEI. A single intravenous administration of Exendin-4 polyplex with ABP polymer resulted in increased Exendin-4 expression and enhanced glucose-induced insulin secretion associated with decreased blood glucose in C57BL/6J mice fed with high-fat diet (HFD).
Viral gene delivery approaches Adenovirus
To increase the efficacy of gene delivery, adenoviral expression vectors encoding GLP-1 7-37 were constructed and systemically injected into db/db mice and ZDF diabetic rats (Ref. 43) . Sustained high levels of circulating active GLP-1 expression that led to a reduced hyperglycaemia were obtained by linking the modified GLP-1-coding region (A8 G substitution to render the peptide resistant to DPP-4 cleavage) to a leader sequence and a furin recognition site. Systemic injection of the adenovirus-GLP-1 vector improved glucose tolerance and reduced food intake generating weight loss in ZDF diabetic rats.
In another approach, DPP-4 resistant GLP-1 7-37 linked to the mouse growth hormone (mGH) secretory sequence with the furin cleavage site was cloned into the adenovirus vector for GLP-1 expression in submandibular glands in mice (Ref. 44 ). Delivery of Ad-GLP-1 resulted in 3 times higher serum GLP-1 levels associated with faster blood glucose clearance and reduction in alloxan-induced hyperglycaemia compared to mice injected with a control vector. Although, GLP-1 released from exocrine cells of the salivary glands could be modified for secretion into the circulatory system to alter blood glucose levels, retroductal infusion of adenovirusmediated GLP-1 gene delivery into salivary glands resulted in an inflammatory reaction due to viral backbone-limiting therapeutic efficacy of GLP-1 peptide.
An adenoviral vector carrying GLP-1 cDNA (rAd-GLP-1) driven by a CMV promoterenhancer and albumin leader sequence was constructed to determine the extent to which continuous GLP-1 expression in vivo could stimulate beta-cell regeneration in mice (Ref. 45) . A single i.v. administration of rAd-GLP-1 into streptozotocin (STZ)-induced diabetic non-obese diabetic-severe combined immunodeficient (NOD/SCID) mice demonstrated that remission of diabetes could be achieved within 10 days and normoglycaemia could be maintained at least 20 days. In addition, rAd-GLP-1-treated mice manifested a higher number of insulinpositive cells in the pancreas leading to high levels of insulin secretion compared to STZ-induced diabetic mice infected with control adenovirus. Thus, regeneration of insulin-producing pancreatic beta cells by GLP-1-mediated gene therapy might be a potential therapeutic strategy for the treatment of diabetes. A new GLP-1 7-37 encoding recombinant adenovirus (Ad-ILGLP-1) with a CMV promoter and insulin leader sequence was constructed and injected i.v. into 12-week-old ZDF rats with overt T2DM (Ref. 46) , resulting inhigh levels of circulating GLP-1 and normoglycaemia for 3 weeks and improved glucose tolerance. Although, both pre-diabetic and diabetic ZDF rats responded similarly to adenovirus-mediated GLP-1 gene delivery, the protection only lasted 21 days due to transient nature of gene expression induced by adenovirus vectors.
Obesity and insulin resistance are linked to lowgrade chronic inflammation (Ref. 47 ). Since, adipose tissue is a source of inflammation contributing to insulin resistance, a recombinant adenovirus producing GLP-1 (rAd-GLP-1) was generated and administered into ob/ob mice to test the extent to which GLP-1 had anti-inflammatory effects on adipose tissue (Ref. 48) . rAd-GLP-1-treated ob/ob mice demonstrated significant reductions in fat mass, adipocyte size and lipogenic mRNA expression compared to untreated mice. A reduction in abdominal fat, but not s.c. fat, is consistent with previous observations indicating that abdominal fat deposition is associated with insulin resistance (Ref. 49) . Direct inhibition of inflammatory pathways in adipocytes (as well as macrophages) suggests that insulin sensitivity was improved by GLP-1.
A helper-dependent adenoviral (HDAd) vector was produced to evaluate the long-term effects of elevated Exendin-4 expression in vivo in a HFDinduced obesity mouse model (Ref. 50) . This model was used instead of the genetic rodent models of extreme obesity to better mimic the metabolic changes that occur in obese patients. A single HDAd-Ex4 injection of HFD mice improved glucose homoeostasis with decreased gluconeogenic enzyme activity. However, this treatment did not lead to increased circulating insulin levels, but it reduced hepatic fat and improved adipokine profile of treated animals. The decreased weight gain observed in HFD mice was attributed to increased energy expenditure, and not a result of a change in food intake.
Adeno associated virus (AAV)
A double-stranded AAV serotype 8 vector (dsAAV8) containing enhanced green-fluorescent protein (eGFP) driven by the mouse insulin-II promoter (MIP) resulted in a tissue specific transduction of pancreatic beta-cells (Ref. 51) . Considering these data, a DsAAV8-MIP construct with GLP-1 instead of eGFP was used to assess therapeutic efficacy of GLP-1 via intraperitoneal injection into diabetic mice with beta-cell damage induced by multiple low-dose STZ administration (Ref. 52) . Despite protection from hyperglycaemia, GLP-1 expression in the beta cells was not high enough to increase circulating GLP-1 levels due to insufficient transduction with dsAAV (27%). The localised intraislet GLP-1 production did, though, significantly improve islet function and survival.
Hepatocyte growth factor (HGF) has also been considered as a therapeutic agent for diabetes (Ref. 53 Integration of viral vectors into the genome is required to achieve long-term gene expression in vivo. Among the integrating vectors, lentiviral vectors appear to be vector of choice because they infect both dividing and non-dividing cells, possess little-to-no immunogenicity and do not cause deleterious mutations (Refs 81, 82). Lentiviral vectors do not mobilise even after infection with wild-type HIV-1, such that they are regarded as safe for clinical applications. Pseudotyping of lentiviral vectors with vesicular stomatitis virus-G protein (VSV-G) is also important to obtain high titre yield with broad tissue tropism (Refs 83, 84). Since no doselimiting toxicities have been reported with lentiviral vectors, there is minimal toxicity concern even after multiple injections. Consequently, lentivirus-mediated GLP-1 gene delivery targeting pancreatic islets either through pseudotyping and/or using tissuespecific promoters might be necessary to improve the therapeutic efficacy and safety of GLP-1-mediated gene therapy approach.
Promoter selection
A number of reports involving GLP-1 gene delivery using viral vectors initially used constitutive promoters such as CMV, chicken β-actin or ubiquitin to provide strong but unregulated GLP-1 7-37 expression. Although these studies clearly demonstrated increased plasma GLP-1 levels that resulted in lowering of blood glucose with improved insulin sensitivity, the site of transgene expression remained elusive. The liver, spleen, heart, pancreas and other tissues were suspected to express the transgene, but the possibility of transgene expression in any given tissue would raise a concern about the long-term safety of this therapeutic approach. In addition, it remains unknown to what extent constant GLP-1 expression would desensitise the GLP-1 receptor creating a GLP-1-resistant status in vivo or cause other side effects. In this sense, the use of tissuespecific promoters might resolve issues with safety and toxicity of gene delivery. Clearly, the choice of promoter is determined by the target tissues in which the transgene expression is desired for. For example, liver-specific expression of GLP-1 gene has successfully been achieved using the L-pyruvate kinase (LPK) promoter (Ref. 85) . This promoter has the additional benefit of supplying regulated promoter function to the transgene of interest in such a way that promoter activity is only elevated when blood glucose increases, such as after meals. This would not only be important for mimicking physiological secretion of GLP-1, but also essential for avoiding possible side effects.
The insulin promoter with glucoregulatory activities is very effective in providing transgene expression specifically in pancreatic beta cells (Ref. 51) . Intraperitoneal delivery of DsAAV8-MIP-GLP-1 provided both localised GLP-1 expression in pancreatic beta cells and protection against the development of STZinduced diabetes in mice. However, localised GLP-1 expression in pancreatic beta cells was not sufficient to increase plasma GLP-1 levels, which limited the broad therapeutic efficacy of GLP-1 relevant for modulating insulin sensitivity, food intake and weight loss. Consequently, the inability to increase the amount of circulating GLP-1 with localised gene expression in the pancreas may limit the interaction of GLP-1 with glucoregulatory tissues involved in the generation of insulin sensitivity and weight loss such as adipocytes, muscle and liver. Since GLP-1 is secreted by intestinal endocrine L cells and acts locally in the gut by inhibiting gastric emptying and gastric acid secretion that leads to decreased food intake and weight loss, restricting GLP-1 expression to pancreatic beta cells may interfere with its beneficial gastrointestinal effects (Ref. 52 ). Direct injection of ssAAV into the pancreas transduced an insufficient number of pancreatic islets to yield a therapeutic effect (Ref. 70) . Conversely, dsAAV vectors have high transduction efficiency compared to ssAAV vectors. To achieve long lasting and strong gene expression in pancreatic islets of C57BL10 mice, three different delivery routes (intraperitoneal, intraductal and intravenous) were compared using dsAAV vectors (Ref. 51) . Intravenous delivery of dsAAV vectors resulted in 5-10-fold less efficient pancreatic transduction compared to intraperitoneal injection since most of the dsAAV were filtered by the liver. Despite this, intraperitoneal delivery primarily transduced cells on the islet peripheral zone compared to cells in central zone due to limited diffusion of viral particles into the islets. Intriguingly, use of a retrograde pancreatic intraductal delivery approach, which is similar to the commonly used clinical technique known as endoscopic retrograde cholangiopancreatography, provided better transduction rates in pancreatic islets expert reviews http://www.expertreviews.org/ in molecular medicine compared to intraperitoneal and intravenous delivery. It is difficult to perform this technique in small animals like mice, such that rats might be a better option to experimentally test retrograde pancreatic intraductal gene delivery due to feasibility and clinical relevance compared to intraperitoneal injection. While topical delivery reduced gene transfer to nonpancreatic tissues (liver, heart, testis, and muscles), transduced cells were still mostly located on the peripheral zone of the islets. Regardless of the route chosen for gene delivery, the insulin promoter was still required for highly specific transgene expression in insulinproducing pancreatic beta cells in vivo, particularly to exclude transgene expression in acinar cells of pancreas. Lastly, the efficacy of dsAAV vector gene delivery to pancreatic islets was tested in C57BL10 mice by way of intravenous delivery in combination with a transient blockade of the liver circulation (Ref. 51) . Although intravenous gene transfer by itself to the pancreatic islets was undetectable using dsAAV vectors, gene transfer to the pancreatic islets was increased 15-fold using the liver blockage approach leading to uniform transgene expression in most of the islets. In this study, different serotypes of AAV vectors were also tested exhibiting various levels of tissue transduction in pancreas depending on the dsAAV serotype.
Site-specific integration

Depository tissues
Due to destruction of pancreatic beta cells during disease progression, ectopic expression of GLP-1 outside the pancreas is another option for therapy. Among the potential sites of expression, the liver initially appeared to be the best target organ for GLP-1 gene delivery due to ease of access, high transduction rates and release of large amount of therapeutic proteins into circulation. Moreover, the enzymes responsible for glucose sensitivity and response, Glucose transporter 2 (GLUT2) and glucokinase, are mainly synthesised in liver, which gives the liver the ability to detect circulating glucose levels in our body (Ref. 97) . This characteristic also made the liver a preferred target organ in islet cell transplantation (Ref. 98 ). However, the liver lacks the regulated secretory system necessary for GLP-1 secretion that is present in endocrine tissues such as intestinal L cells, making it necessary for further modifications to GLP-1 for successful synthesis and secretion from liver. Inclusion of a signal peptide to direct GLP-1 into secretory pathways following posttranslational modifications solved one of the problems associated with GLP-1 synthesis in liver. The liver is also one of the two organs in which furin endopeptidases are synthesised, so inclusion of a furin recognition sequence after the secretory signal peptide to liberate GLP-1 from its secretory signal increased GLP-1 production by the liver (Ref. 99) . While most of the recent experimental gene therapy studies included vectors with some or all the features mentioned above (Fig. 3) , utilisation of the hidden Marcov model might be useful in designing of the most efficient human secretory signal peptides for GLP-1 secretion (Ref. 100) . Salivary glands are also becoming a frequently targeted depository organ to synthesise GLP1, since they have the capacity to synthesise large amount of protein that can be secreted into the bloodstream. One potential benefit of targeting the salivary gland is that it is surrounded with a capsule, which would restrict vector distribution minimising side effects of the treatment. If adverse events were to occur following gene delivery, removal of the salivary glands would be easy and safe since they are not essential for life. Because of these characteristics, salivary glands have been evaluated as a surrogate endocrine gland using gene therapy for the correction of many inherited monogenetic endocrine disorders (Ref. 
Molecular alterations concerning GLP-1 gene therapy targeting pancreas
The mechanism of GLP-1-mediated islet cell protection was investigated by global gene expression profiling of pancreatic islets isolated from STZ-induced diabetic mice (Ref. 104 ). There was strong induction of p53-responsive genes and suppression of a wide range of diabetes-related genes with short-term low-dose STZ treatment. REG3 family proteins, like GLP-1, act as a beta-cell trophic factor with the potential to reverse STZ-induced hyperglycaemia through islet neogenesis (Ref. 105 ). An AAV9-based beta-cell-targeted gene transfer system involving REG3B-GLP-1 fusion protein expression was designed to achieve maximum beta-cell trophic effect in diabetic mice. Overexpression of REG3B-GLP-1 preserved beta-cell mass and protected mice from STZ-induced diabetes (Ref. 104 ). REG3B-GLP-1 gene therapy did not drastically alter STZ-induced changes in the islets as defined by the global gene expression profile, but the REG3B-GLP-1 gene therapy was able to suppress islet cell apoptosis by enhancing expression of genes involved in beta-cell survival. Intriguingly, most of the STZ downregulated genes were related to genes involved in beta-cell function and development -not the housekeeping genes.
Animal models
Most of the experimental gene therapy studies involving GLP-1 gene delivery have been performed in genetically controlled rodent obesity models, such as ob/ob, db/db and Zucker diabetic rats (Refs 35, 37, 43, 106) . Since these models carry mutations in genes that affect appetite (leptin (ob/ob) or leptin receptors (db/ db, zucker diabetic fa/fa rats)), the use of genetically modified animal models of diabetes may not be ideal for long-term studies of metabolic changes (Ref. 107) . The most appropriate experimental animal model of a human disease is the model that can best mimic the pathophysiology of a human disease of interest. In addition, model standardisation, continuity, cost, clinical benefits and widespread utilisation by scientists are among the factors influencing the decision-making process. Since T2DM in humans arises from the interaction between genes and the environment, DIO combined with low-dose STZ injection (to induce beta-cell loss and hyperglycaemia) appears to be the best model to mimic the actual disease process (Fig. 4) . Thus, the real antidiabetic potential of GLP-1-mediated gene therapy approach may require testing the efficacy of treatment with a third generation HIV-based lentiviral vector to deliver GLP-1 in a HFD, low-dose STZ-induced diabetes model. However, additional doses of virus might be needed to transduce target tissues to Induction of obesity in C57BL/6 mice Expert Reviews in Molecular Medicine © 2014 Cambridge University Press Figure 4 . Induction of obesity in C57BL/6 mice. Eight-week-old C57BL/6 male mice were fed a standard diet (SD-left panel) or high-fat diet (HFDright panel) where 60% of the total calories come from fat. After glucose tolerance and insulin sensitivity tests, low-dose STZ injection is needed to induce diabetes. Arrows indicate abdominal fat deposition. Incretins were first proposed for the treatment of T2DM in 1992, but the first incretin mimetic (Exenatide) for commercial use was approved by the U.S. . Several other incretin mimetics have reached to market since 2010, and there are even more incretin-based drugs under development. As with any drug, there are some risks associated with the benefits of using incretin-based treatments. For example, Exenatide and Liraglutide have been reported to cause significant gastrointestinal discomfort in T2DM patients (Refs 114, 115), but it remains to be determined the extent to which they are associated with increased risk for pancreatitis or pancreatic cancer (Ref. 116) . Nevertheless, these drugs require daily s.c. injections (once/day for Liraglutide and twice/day for Exenatide) to be effective. Thus, experimental viral or non-viral gene delivery methods have been under development to supply a constant GLP-1 production and secretion for the treatment of diabetes (Table 1) . Even though gene therapy appears to be a promising technique for achieving a long-term increase in GLP-1 synthesis and secretion, the most effective gene delivery method has yet to be identified. Protocols using dsAAV vectors have produced some successful results, similar or enhanced results are expected using lentivirus vectors targeting pancreas with glucoregulatory function. This is especially true when the long-term beneficial neuroprotective and/or cardioprotective effects of GLP-1 are expected. GLP-1 gene delivery has produced favourable results in both pre-diabetic and fully diabetic animals, suggesting that a GLP-1 gene therapy approach may be a reasonable alternative to constant infusions or daily injections of GLP-1 peptide. It is important to keep in mind, though, that many of these published results showing the benefits of GLP-1 gene therapy were conducted in small rodent models of T2DM, making it crucial to continue testing of this therapy in larger animal models (such as cats, dogs, pigs and even primates) to increase the clinical relevance of experimental findings and design future clinical trials. 
